Universiẗat, Diss., 2006--Giessen.

Universiẗat, Diss., 2006--Giessen.

Submitted by Fabio Sobreira Campos da Costa (fabio.sobreira@ufpe.br) on 2016-01-18T13:52:56Z No. of bitstreams: 3 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) DISSERTAÇÃO HICLA MOREIRA.pdf: 1214693 bytes, checksum: c19232269889cb62e41e1263d8a9832a (MD5) DISSERTAÇÃO HICLA MOREIRA.pdf: 1214693 bytes, checksum: c19232269889cb62e41e1263d8a9832a (MD5) / Made available in DSpace on 2016-01-18T13:52:56Z (GMT). No. of bitstreams: 3 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) DISSERTAÇÃO HICLA MOREIRA.pdf: 1214693 bytes, checksum: c19232269889cb62e41e1263d8a9832a (MD5) DISSERTAÇÃO HICLA MOREIRA.pdf: 1214693 bytes, checksum: c19232269889cb62e41e1263d8a9832a (MD5) Previous issue date: 2015-08-31 / O envelhecimento prejudica a função endotelial, o que pode ser considerado um marco do desenvolvimento de doenças cardiovasculares em idosos. O cilostazol, um inibidor seletivo da fosfodiesterase 3 (PDE-3), tem efeitos antiplaquetário, antitrombótico e vasodilatador. No presente estudo foi analisado se o tratamento com cilostazol melhora a função vascular (mecanismos contráteis e relaxamento) de ratos idosos e os possíveis mecanismos envolvidos. Ratos Wistar machos com 18 meses de idade foram tratados com cilostazol durante 8 semanas com uma dose de 100 mg/kg/dia administrado por gavagem. Ratos não tratados receberam apenas veículo. A pressão arterial média e a frequência cardíaca foram medidas nos ratos acordados. Artérias mesentéricas de resistência (AMR) foram utilizadas para avaliar o relaxamento à acetilcolina, ao nitroprussiato de sódio (NPS), à forskolina e ao isoproterenol, e a contração induzida pela noradrenalina, enquanto o relaxamento à forskolina e ao isoproterenol permaneceu inalterado em ambos os grupos, o relaxamento à acetilcolina e ao NPS foi potencializado em AMR de ratos tratados com cilostazol. Nessas artérias, a vasoconstrição à noradrenalina foi semelhante nos dois grupos. A incubação com L-NAME ou ODQ aboliu a resposta vasodilatadora à acetilcolina em AMR de ambos os grupos. Entretanto, na presença de L-NAME e indometacina, o relaxamento à acetilcolina foi semelhante nos dois grupos. O bloqueio de canais para K+ ativados por Ca2+ (KCa) (apamina + TRAM-34) reduziu o relaxamento induzido pela acetilcolina em AMR de ratos tratados com cilostazol, mas não em ratos não tratados. Em resumo, os resultados sugerem que o cilostazol normaliza a função endotelial em ratos idosos por um mecanismo dependente de GMPc, envolvendo provavelmente um aumento da liberação de •NO e subsequente ativação de canais KCa no músculo liso vascular. Embora mais estudos sejam necessários, estes resultados indicam um possível uso de cilostazol como uma alternativa para a prevenção/ tratamento de desordens vasculares induzidas pelo envelhecimento. / Aging impairs endothelial function, which may be considered a hallmark of the development of cardiovascular diseases in elderly. Cilostazol, a selective inhibitor of phosphodiesterase 3 (PDE-3), has antiplatelet, antithrombotic and peripheral vasodilator effects. In the current study, we analyzed whether cilostazol could affect vascular function (contractile and relaxation mechanisms) of old rats and possible mechanism involved. 18-month-old male Wistar rats were treated with Cilostazol during 8 weeks at the dose of 100 mg.kg-1 by gavage. The untreated rats received vehicle alone. Mean arterial pressure and heart rate were measured in conscious rats. Mesenteric resistance arteries were used to evaluate the relaxation to acetylcholine, sodium nitroprusside, forskolin, and isoproterenol and noradrenaline-induced contraction, while relaxation to forskolin and isoproterenol remained unmodified by cilostazol, relaxation to acetylcholine and to SNP was increased in MRA from cilostazol-treated than untreated rats. In these arteries, vasoconstriction produced by noradrenaline was similar in both groups. The incubation with L-NAME or ODQ abolished the vasodilator response to acetylcholine in MRA from both cilostazol-treated and untreated rats. However, in presence of L-NAME and indomethacin, relaxation to acetylcholine was similar in both groups. The blockade of calcium-activated K+-channel (KCa) (TRAM-34 plus apamin) attenuated acetylcholine-induced relaxation in MRA from cilostazol-treated rats, but in untreated rats. In short, results suggests that cilostazol reverses endothelial function in aged rats by a cGMP-dependent mechanism, involving probably an increase in •NO and subsequent activation of the KCa channel in vascular smooth muscle. Although further study is needed, these results indicate a possible use of cilostazol as an alternative for the prevention/ treatment of vascular disorders induced by aging.

Orientador: Elaine Minatel / Dissertação (mestrado) - Universidade Estadual de Campinas, Instituto de Biologia / Made available in DSpace on 2018-08-27T05:53:09Z (GMT). No. of bitstreams: 1 Hermes_TuliodeAlmeida_M.pdf: 2416913 bytes, checksum: 6780cc171b5db72eb9dd72aa61ad89b1 (MD5) Previous issue date: 2015 / Resumo: Estresse oxidativo e resposta inflamatória exacerbada são fatores que contribuem com a fisiopatogênese da distrofia muscular de Duchenne (DMD). No presente trabalho, avaliamos se a administração de Cilostazol, antes que se iniciem os ciclos degeneração/regeneração, diminui a degeneração muscular em camundongos mdx, modelo experimental da DMD. Nossa hipótese é que o Cilostazol possa apresentar efeito benéfico sobre as fibras musculares distróficas, uma vez que, este apresenta efeitos anti-inflamatório (reduzindo a expressão de citocinas pró-inflamatórias como o TNF-?, IL-1? e IL-6) e antioxidante (diminuindo a atividade de superóxido e eliminando radicais hidroxilas). Para verificar o efeito do cilostazol sobre as fibras musculares distróficas, camundongos mdx, com 14 dias de vida, receberam por gavagem 100 mg/kg de Cilostazol, por 14 dias consecutivos (grupo mdxC). Camundongos mdx não tratados (grupo mdx) e da linhagem C57BL/10 (grupo Ctrl) foram utilizados como controle. A análise de medida de força realizada em todos os animais (antes e após o período de tratamento) demonstrou que os animais do grupo mdxC apresentaram maior força muscular (cerca de 32%) em relação ao grupo mdx. Na análise bioquímica da degeneração muscular (análise de creatina quinase- CK em amostras de sangue), observou-se aumento significativo nos níveis séricos de CK nos camundongos mdx em relação aos animais controle e redução significativa de 63,2% deste aumento nos mdx tratados com Cilostazol. Na análise histológica dos músculos bíceps braquial (BB), diafragma (DIA) e tibial anterior (TA), verificou-se redução de 93,6% de fibras em degeneração (indicadas pela marcação com azul de Evans) no músculo BB, redução de 66,6% e 36,7% de fibras regeneradas (indicadas pela presença de núcleo centralizado) nos músculos TA e DIA, respectivamente e redução de 39,1% na área de inflamação no músculo BB dos animais do grupo mdxC em relação ao grupo mdx. Através da técnica de western blotting, moléculas envolvidas no processo inflamatório como o TNF-? e NF-?B e um dos produtos da peroxidação lipídica, o 4-HNE, foram analisados nos músculos BB, DIA e TA. Nos animais do grupo mdxC, observou-se diminuição significativa no conteúdo de TNF-? nos músculos DIA (48,5%), TA (35,4%) e BB (45,9%) em relação ao controle. O conteúdo de NF-?B apresentou-se reduzido 25,9% no músculo DIA. O conteúdo de 4-HNE reduziu nos músculos analisados do grupos mdxC, porém esta redução não foi significativa. Na reação Dihydroetidio (DHE) para detecção de espécies reativas de oxigênio, o tratamento com Cilostazol demonstrou ser potencialmente eficaz contra o estresse oxidativo, reduzindo a marcação de DHE em 36,8%, 40,4%, e 75,4% nos músculos BB, TA e DIA, respectivamente. Na análise de vascularização, observamos que os animais tratados com Cilostazol apresentaram aumento da densidade de microvasos no tecido muscular (cerca de 42,7% para o músculo BB e 15,3% para o músculo DIA). Em relação à análise da atividade antioxidante no músculo quadríceps (QUA), identificamos aumento na quantidade de GSH (33,1%) e na atividade da GR (89,1%), no grupo mdx em relação ao Ctrl. Em relação ao tratamento, este não apresentou efeito sobre a atividade antioxidante. O conjunto dos resultados nos permite sugerir que o Cilostazol apresenta potencial efeito benéfico sobre as fibras musculares distróficas / Abstract: Oxidative stress and exacerbated inflammatory response are factors that contribute to Duchenne muscular dystrophy (DMD) pathogenesis. In this work, we evaluated whether administration of Cilostazol, before beginning the degeneration/regeneration cycles, reduces muscle degeneration in mdx mice, an experimental model of DMD. Our hypothesis is that the Cilostazol may provide beneficial effects on dystrophic muscle fibers, since this has anti-inflammatory effects (reducing the expression of proinflammatory cytokines such as TNF-?, IL-1? and IL-6) and antioxidant (decreasing the activity of superoxide and eliminating hydroxyl radicals). To evaluate the Cilostazol effects on dystrophic muscle fibers, mdx mice, 14 days old, received by gavage 100 mg/kg of Cilostazol for 14 consecutive days (mdxC group). Mdx mice untreated (mdx group) and C57BL/10 mice (group Ctrl) were used as controls. Analysis strength measurement performed in all animals (before and after the treatment period) demonstrated that the animals of the mdxC group higher muscle strength (by 32%) compared to mdx group. In biochemical analysis of muscle degeneration (creatina kinase ¿ CK analysis in blood samples), there was significant increase in CK levels in mdx mice compared to control animals and a significant reduction by 63.2% of this increase in Cilostazol treated mdx. Histological analysis of the biceps brachial (BB), diaphragm (DIA) and tibial anterior (TA), showed a reduction of 93.6% of degenerating fibers (indicated by labeling with Evans blue) in the BB muscle, reduction of 66.6% and 36.7% of regenerated fibers (defined by central nuclei presence) in TA and DIA muscles respectively, and a reduction by 39.1% in inflammation area in BB muscle of mdxC group compared to mdx group. By the western blotting technique, molecules involved in inflammation such as TNF-? and NF-?B and one of the lipid peroxidation product, 4-HNE, were analyzed in the BB, DIA and TA muscles. In animals of mdxC group, we observed a significant decrease in TNF-? content in DIA (48.5%), TA (35.4%) and BB (45.9%) compared to control muscles. The NF-?B content had been reduced by 25.9% in the DIA muscle. The 4-HNE content reduced in the muscles analyzed in mdxC groups, but this reduction was not significant. In Dihydroethidium (DHE) reaction for detecting reactive oxygen species, treatment with Cilostazol shown to be potentially effective against oxidative stress, reducing DHE marking by 36.8%, 40.4% and 75.4% in BB, TA and DIA muscles, respectively. In the vasculature analysis, we observed that cilostazol treated animals showed increased microvessel density in muscle tissue (approximately by 42.7% for the BB muscle and 15.3% for DIA muscle). On the analysis of antioxidant activity in the quadriceps (QUA), we identified an increase in the GSH content (33.1%) and GR activity (89.15) in the mdx group compared to Ctrl group. Regarding treatment, this had no effect on antioxidant activity. The results together suggest that cilostazol has a potential beneficial effect on the dystrophic muscle fibers / Mestrado / Anatomia / Mestre em Biologia Celular e Estrutural

Background: The recent literature has shown that triple antiplatelet therapy with cilostazol in addition to the standard dual antiplatelet therapy with aspirin and clopidogrel may reduce platelet reactivity and improve clinical outcomes following percutaneous coronary intervention. The purpose of this meta-analysis is to compare the efficacy of triple antiplatelet therapy and dual antiplatelet therapy in regard to on-treatment platelet reactivity. Methods: Nine studies (n = 2179) comparing on-treatment platelet reactivity between dual antiplatelet therapy (n = 1193) and triple antiplatelet therapy (n = 986) in patients undergoing percutaneous coronary intervention were included. Primary end points were P2Y12 reaction unit (PRU) and platelet reactivity index (PRI). Secondary end points were platelet aggregation with adenosine diphosphate (ADP) 5 and 20 μmol/L and P2Y12% inhibition. Mean difference (MD) and 95% confidence intervals (CI) were computed and 2-sided α error <.05 was considered as a level of significance. Results: Compared to dual antiplatelet therapy, triple antiplatelet therapy had significantly lower maximum platelet aggregation with ADP 5 μmol/L (MD: -14.4, CI: -21.6 to -7.2, P < .001) and 20 mmol/L (MD: -14.9, CI: -22.9 to -6.8, P < .001), significantly lower PRUs (MD: -45, CI: -59.4 to -30.6, P < .001) and PRI (MD: -26, CI: -36.8 to -15.2, P < .001), and significantly higher P2Y12% inhibition (MD: 18.5, CI: 2.3 to 34.6, P = .025). Conclusion: Addition of cilostazol to conventional dual antiplatelet therapy significantly lowers platelet reactivity and may explain a decrease in thromboembolic events following coronary intervention; however, additional studies evaluating clinical outcomes will be helpful to determine the benefit of triple antiplatelet therapy.

Background: The recent literature has shown that triple antiplatelet therapy with cilostazol in addition to the standard dual antiplatelet therapy with aspirin and clopidogrel may reduce platelet reactivity and improve clinical outcomes following percutaneous coronary intervention. The purpose of this meta-analysis is to compare the efficacy of triple antiplatelet therapy and dual antiplatelet therapy in regard to on-treatment platelet reactivity. Methods: Nine studies (n = 2179) comparing on-treatment platelet reactivity between dual antiplatelet therapy (n = 1193) and triple antiplatelet therapy (n = 986) in patients undergoing percutaneous coronary intervention were included. Primary end points were P2Y12 reaction unit (PRU) and platelet reactivity index (PRI). Secondary end points were platelet aggregation with adenosine diphosphate (ADP) 5 and 20 μmol/L and P2Y12% inhibition. Mean difference (MD) and 95% confidence intervals (CI) were computed and 2-sided α error <.05 was considered as a level of significance. Results: Compared to dual antiplatelet therapy, triple antiplatelet therapy had significantly lower maximum platelet aggregation with ADP 5 μmol/L (MD: -14.4, CI: -21.6 to -7.2, P < .001) and 20 mmol/L (MD: -14.9, CI: -22.9 to -6.8, P < .001), significantly lower PRUs (MD: -45, CI: -59.4 to -30.6, P < .001) and PRI (MD: -26, CI: -36.8 to -15.2, P < .001), and significantly higher P2Y12% inhibition (MD: 18.5, CI: 2.3 to 34.6, P = .025). Conclusion: Addition of cilostazol to conventional dual antiplatelet therapy significantly lowers platelet reactivity and may explain a decrease in thromboembolic events following coronary intervention; however, additional studies evaluating clinical outcomes will be helpful to determine the benefit of triple antiplatelet therapy.

Submitted by Eunice Novais (enovais@uepg.br) on 2018-09-06T16:39:14Z No. of bitstreams: 2 license_rdf: 811 bytes, checksum: e39d27027a6cc9cb039ad269a5db8e34 (MD5) Nubia Nascimento.pdf: 1296891 bytes, checksum: 1fb7f4ddd43a4591eeb9f1b8e95bb14f (MD5) / Made available in DSpace on 2018-09-06T16:39:14Z (GMT). No. of bitstreams: 2 license_rdf: 811 bytes, checksum: e39d27027a6cc9cb039ad269a5db8e34 (MD5) Nubia Nascimento.pdf: 1296891 bytes, checksum: 1fb7f4ddd43a4591eeb9f1b8e95bb14f (MD5) Previous issue date: 2018-05-28 / O cilostazol é um inibidor seletivo da fosfodiesterase III que atua como antiagregante plaquetário e vasodilatador. Faz parte do tratamento clínico da doença aterosclerótica carotídea extracraniana,apresentando benefícios para o adequado fluxo sanguíneo local.Devido à suacaracterística lipofílica,é um excelente fármaco para o estudo do desenvolvimento de sistemas de liberação modificada, que objetivam melhorar a disponibilidade biológica. A aplicação de tecnologias em formulações, como nanosuspensões, caracteriza uma estratégia atrativa para melhorar a ação de compostos pouco solúveis em água como o Cilostazol. Este trabalho avalioua ação do Cilostazolnanoencapsulado na túnica média da artéria carótida esquerda e no perfil lipídico de ratos Wistar. Os animais foram divididos em 4 grupos, que receberam soluções de nanocápsulas contendo cilostazol, nanocápsulas sem cilostazol, solução de propilenoglicol e cilostazol pesado.Foi observada diferença entre a espessura da carótida em micrômetros, entre os grupos que receberam o cilostazolnanoencapsulado e o grupo que recebeu a solução de propilenoglicol [70.22(9.2±47-81)IC95% 62-72] (P 0,019), sendo a maior espessura observada no grupo que recebeu o cilostazolnanoencapsulado. Não houve diferença em relação à celularidade em números absolutos, entre os grupos. Em relação ao perfil lipídico, o grupo que recebeu propilenogicol apresentou valores maiores de HDL comparativamente ao grupo que recebeu a solução de cilostazolnanoencapsulado [56.85(10.5±37.7-83.7)IC95% 52.56-61.38] (P0,01). O nível de triglicerídeos em mg/dL foi maior no grupo que recebeu o cilostazolpesado em relação ao grupo que recebeu a solução de nanocápsulas [116,92(56.37±45-266)IC95% 74.15-132.33] (P0,01). O cilostazol pesado apresentou melhores resultados em relação ao perfil lipídico. A apresentação do cilostazolnanoecapsulado não demonstrou ser adequada para o tratamento da doença carotídea extracraniana devido ao fato de aumentar o perfil lipídico dos animais estudados. A estrutura da nanocápsula, por conter lipídios em seu interior, piorou o perfil lipídico. Os achados laboratoriais foram condizentes com os achados histopatológicos. / Cilostazol is a selective inhibitor of phosphodiesterase III that acts as a platelet antiaggregant and vasodilator. It is part of the clinical treatment of extracranial atherosclerotic carotid disease, presenting benefits for adequate local blood flow. Due to its lipophilic characteristics, it is an excellent drug for the study of the development of modified release systems, which aim to improve biological availability. The application of technologies in formulations, such as nanosuspensions, characterizes an attractive strategy to improve the action of compounds little soluble in water like Cilostazol. This study evaluated the effect of nanoencapsulated Cilostazol on the left carotid artery layers and in the lipid profile of Wistar rats. The animals were divided into 4 groups, which received solutions of nanocapsules containing cilostazol, nanocapsules without cilostazol, solution of propylene glycol and heavy cilostazol. Differences were observed between carotid thickness in micrometers between groups receiving nanoencapsulated cilostazol and the group receiving the propylene glycol solution (70.22 (9.2 ± 47-81) 95% CI 62-72) (P <0.019), with the highest thickness observed in the group receiving nanoencapsulated cilostazol. There was no difference in cellularity in absolute numbers between the groups. Regarding the lipid profile, the group receiving propylene glycol had higher values of HDL in mg/dL, compared to the group that received the nanoencapsulated cilostazol solution [56.85 (10.5 ± 37.7-83.7) 95% CI 52.56-61.38] (P 0.01). The level of triglycerides in mg/dL was higher in the group that received the heavy cilostazol compared to the group that received the nanocapsule solution [116 (56.37 ± 45-116.92) CI95% 74.15-132.33] (P 0.01). The heavy cilostazol presented better results in relation to the lipid profile. The presentation of nanoecapsulated cilostazol has not been shown to be adequate for the treatment of extracranial carotid disease due to the fact that it increases the lipid profile of the animals studied. The structure of the nanocapsule, as it contained lipids, worsened the lipid profile. Laboratory findings were consistent with histopathological findings.

The pharmacological development of non-steroidal contraceptives has yet to be achieved. Arresting oocyte maturation without blocking ovulation has been evaluated using different inhibitors of the phosphodiesterase 3A (PDE3A). Unfortunately, PDE3A is also expressed in the heart and blood vessels, and inhibition of PDE3A in oocytes can produce cardiovascular side effects. We reviewed the literature on available PDE3 inhibitors and selected cilostazol (CLZ), which is an FDA approved therapeutic. CLZ has the ability to decrease cellular adenosine uptake and consequently antagonizes side effects of PDE3A inhibition in vital organs. CLZ inhibited oocyte meiotic maturation in vitro. CLZ has more degenerative impact on arrested oocytes than matured oocytes, indicating that prolonged meiotic arrest of oocytes is harmful. Administration of CLZ any time from 9h before the ovulatory stimulus to 4h after the stimulus resulted in ovulation of immature oocytes. Controlling CLZ dose, time of CLZ administration, and time of oocyte collection resulted in ovulation of oocytes at different meiotic stages. Oral administrations of CLZ in naturally cycling mice were also observed to block pregnancy whereas remating of those previously treated females resulted in normal offspring and litter sizes. Therefore, CLZ does not only have a wide margin of contraception but also is reversible. Ovulated immature oocytes were observed to have higher rates of advanced chromatin configuration and cortical granule distribution, normal spindle and chromosomal organization, maturation, and in vitro fertilization (IVF) than ovarian immature oocytes. Ovulated metaphase I oocytes that were matured in vitro or in vivo had higher IVF rates than ovulated mature oocytes. Ovulated germinal vesicle (GV) oocytes that were in vitro matured also showed higher IVF rates but when in vivo matured, they had lower IVF rates than ovulated mature oocytes because of the high degeneration and low fertilization rates associated with in vivo maturation of GV oocytes. In summary, CLZ merits further evaluation as a non-steroidal contraceptive and is capable of producing oocytes of various meiotic stages with advanced developmental features.

Objetivo: Avaliar se a administração sistêmica de cilostazol reduz a hiperplasia neointimal nas artérias ilíacas de suínos submetidas a angioplastia com cateter balão. Métodos: O trabalho foi desenvolvido na Unidade de Experimentação Animal do Hospital de Clínicas de Porto Alegre. Vinte suínos foram submetidos a angioplastia com cateter balão 6 x 40 mm na artéria ilíaca comum direita, guiada por ultrassonografia com Doppler. Os animais foram randomizados em dois grupos: grupo 1 (n = 10), no qual foi administrado cilostazol 50 mg em duas doses diárias, e grupo 2 (n = 10), considerado controle. Após 30 dias, os animais foram sacrificados, e as artérias ilíacas preparadas para análise histológica. Os cortes histológicos foram digitalizados e analisados por morfometria digital. A análise estatística foi realizada com o teste t de Student e o de Mann-Whitney. Resultados: Comparando as artérias ilíacas submetidas a angioplastia com as não submetidas a angioplastia, houve hiperplasia neointimal significativa (0,228 versus 0,119 mm2; p = 0,0001). Nas artérias submetidas a angioplastia, não houve diferença entre o grupo 1 (cilostazol) e o grupo 2 (controle) na área do lúmen (2,277 versus 2,575 mm2; p = 0,08), área da íntima (0,219 versus 0,237 mm2; p = 0,64), área da média (2,262 versus 2,393 mm2; p = 0,53) e no percentual de obstrução neointimal (8,857 versus 9,257 %; p = 0,82). Conclusão: O uso de cilostazol 50 mg em duas doses diárias não reduziu a hiperplasia neointimal em artérias ilíacas de suínos submetidas a angioplastia com cateter balão. / Objective: To evaluate whether systemic administration of cilostazol reduces neointimal hyperplasia in the iliac arteries of pigs after balloon angioplasty. Methods: This study was conducted in the Experimental Animal Unit of Hospital de Clínicas de Porto Alegre, Brazil. Twenty pigs underwent angioplasty of the right common iliac artery under Doppler ultrasound guidance using 6x40-mm balloon catheters. The animals were randomized to one of two groups: group 1 (n = 10) received 50 mg cilostazol in two doses a day; and group 2 (n = 10) was the control group. After 30 days, the animals were killed and their iliac arteries were prepared for histological analysis. Histological images were digitalized and analyzed using digital morphometry. The Student t and the Mann-Whitney tests were used for statistical analyses. Results: Iliac arteries that underwent angioplasty had significantly more neointimal hyperplasia than those with no angioplasty (0.228 versus 0.119 mm2; p = 0.0001) Group 1 (cilostazol) and 2 (control) had no significant differences in lumen (2.277 versus 2.575 mm2; p = 0.08), intima (0.219 versus 0.237 mm2; p = 0.64) or media (2.262 versus 2.393 mm2; p = 0.53) area, or in percentage of neointimal obstruction (8.857 versus 9.257 %; p = 0.82). Conclusion: The use of 50 mg cilostazol in two doses a day did not reduce neointimal hyperplasia in iliac arteries of pigs that underwent balloon angioplasty.

Objetivo: Avaliar se a administração sistêmica de cilostazol reduz a hiperplasia neointimal nas artérias ilíacas de suínos submetidas a angioplastia com cateter balão. Métodos: O trabalho foi desenvolvido na Unidade de Experimentação Animal do Hospital de Clínicas de Porto Alegre. Vinte suínos foram submetidos a angioplastia com cateter balão 6 x 40 mm na artéria ilíaca comum direita, guiada por ultrassonografia com Doppler. Os animais foram randomizados em dois grupos: grupo 1 (n = 10), no qual foi administrado cilostazol 50 mg em duas doses diárias, e grupo 2 (n = 10), considerado controle. Após 30 dias, os animais foram sacrificados, e as artérias ilíacas preparadas para análise histológica. Os cortes histológicos foram digitalizados e analisados por morfometria digital. A análise estatística foi realizada com o teste t de Student e o de Mann-Whitney. Resultados: Comparando as artérias ilíacas submetidas a angioplastia com as não submetidas a angioplastia, houve hiperplasia neointimal significativa (0,228 versus 0,119 mm2; p = 0,0001). Nas artérias submetidas a angioplastia, não houve diferença entre o grupo 1 (cilostazol) e o grupo 2 (controle) na área do lúmen (2,277 versus 2,575 mm2; p = 0,08), área da íntima (0,219 versus 0,237 mm2; p = 0,64), área da média (2,262 versus 2,393 mm2; p = 0,53) e no percentual de obstrução neointimal (8,857 versus 9,257 %; p = 0,82). Conclusão: O uso de cilostazol 50 mg em duas doses diárias não reduziu a hiperplasia neointimal em artérias ilíacas de suínos submetidas a angioplastia com cateter balão. / Objective: To evaluate whether systemic administration of cilostazol reduces neointimal hyperplasia in the iliac arteries of pigs after balloon angioplasty. Methods: This study was conducted in the Experimental Animal Unit of Hospital de Clínicas de Porto Alegre, Brazil. Twenty pigs underwent angioplasty of the right common iliac artery under Doppler ultrasound guidance using 6x40-mm balloon catheters. The animals were randomized to one of two groups: group 1 (n = 10) received 50 mg cilostazol in two doses a day; and group 2 (n = 10) was the control group. After 30 days, the animals were killed and their iliac arteries were prepared for histological analysis. Histological images were digitalized and analyzed using digital morphometry. The Student t and the Mann-Whitney tests were used for statistical analyses. Results: Iliac arteries that underwent angioplasty had significantly more neointimal hyperplasia than those with no angioplasty (0.228 versus 0.119 mm2; p = 0.0001) Group 1 (cilostazol) and 2 (control) had no significant differences in lumen (2.277 versus 2.575 mm2; p = 0.08), intima (0.219 versus 0.237 mm2; p = 0.64) or media (2.262 versus 2.393 mm2; p = 0.53) area, or in percentage of neointimal obstruction (8.857 versus 9.257 %; p = 0.82). Conclusion: The use of 50 mg cilostazol in two doses a day did not reduce neointimal hyperplasia in iliac arteries of pigs that underwent balloon angioplasty.